474 related articles for article (PubMed ID: 21680990)
1. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Cook W; Bryzinski B; Slater J; Frederich R; Allen E
Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
9. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Hollander PL; Li J; Frederich R; Allen E; Chen R;
Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Hollander P; Li J; Allen E; Chen R;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
[TBL] [Abstract][Full Text] [Related]
12. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
DeFronzo RA; Hissa MN; Garber AJ; Luiz Gross J; Yuyan Duan R; Ravichandran S; Chen RS;
Diabetes Care; 2009 Sep; 32(9):1649-55. PubMed ID: 19478198
[TBL] [Abstract][Full Text] [Related]
14. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
[TBL] [Abstract][Full Text] [Related]
18. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
LaSalle JR
Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Gu W; Liang L; Wang S; Wang Y; Wu Y; Tian J; Yang G; Piao C; Li Y; Yin J; Xin X; Tan X; Ning G; Wang W;
J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
